Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Utilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug.

Wang JH, Endsley AN, Green CE, Matin AC.

BMC Cancer. 2016 Jul 25;16:524. doi: 10.1186/s12885-016-2508-6.

2.

Evaluation of Ebola Virus Inhibitors for Drug Repurposing.

Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov A, Davey R, Manger ID, Gilfillan L, Bavari S, Tanga MJ.

ACS Infect Dis. 2015 Jul 10;1(7):317-26. doi: 10.1021/acsinfecdis.5b00030. Epub 2015 May 11.

PMID:
27622822
3.

Site-specific Substitutions Eliminate Aggregation Properties of Hemopressin.

Song B, Kibler PD, Endsley AN, Nayak SK, Galande AK, Jambunathan K.

Chem Biol Drug Des. 2015 Dec;86(6):1433-7. doi: 10.1111/cbdd.12610. Epub 2015 Jul 20.

PMID:
26109481
4.

Biodistribution of the multidentate hydroxypyridinonate ligand [(14) C]-3,4,3-LI(1,2-HOPO), a potent actinide decorporation agent.

Choi TA, Endsley AN, Bunin DI, Colas C, An DD, Morales-Rivera JA, Villalobos JA, Shinn WM, Dabbs JE, Chang PY, Abergel RJ.

Drug Dev Res. 2015 May;76(3):107-22. doi: 10.1002/ddr.21246. Epub 2015 Apr 6.

PMID:
25857483
5.

(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.

Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, O'Loughlin KG, Shackleford DM, Justino de Almeida M, Carrillo AK, Clark JA, Dennis AS, Diep J, Deng X, Duffy S, Endsley AN, Fedewa G, Guiguemde WA, Gómez MG, Holbrook G, Horst J, Kim CC, Liu J, Lee MC, Matheny A, Martínez MS, Miller G, Rodríguez-Alejandre A, Sanz L, Sigal M, Spillman NJ, Stein PD, Wang Z, Zhu F, Waterson D, Knapp S, Shelat A, Avery VM, Fidock DA, Gamo FJ, Charman SA, Mirsalis JC, Ma H, Ferrer S, Kirk K, Angulo-Barturen I, Kyle DE, DeRisi JL, Floyd DM, Guy RK.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. doi: 10.1073/pnas.1414221111. Epub 2014 Dec 1. Erratum in: Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):E5764.

6.

β-Carotene Biosynthesis in Probiotic Bacteria.

Miller JK, Harrison MT, D'Andrea A, Endsley AN, Yin F, Kodukula K, Watson DS.

Probiotics Antimicrob Proteins. 2013 Jun;5(2):69-80. doi: 10.1007/s12602-013-9133-3.

PMID:
26782732
7.

Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein α.

Jambunathan K, Watson DS, Endsley AN, Kodukula K, Galande AK.

FEBS Lett. 2012 Jul 30;586(16):2507-12. doi: 10.1016/j.febslet.2012.06.015. Epub 2012 Jun 27.

8.

Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles.

Endsley AN, Ho RJ.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):417-24. doi: 10.1097/QAI.0b013e3182653c1f.

9.

Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells.

Endsley AN, Ho RJ.

AAPS J. 2012 Jun;14(2):225-35. doi: 10.1208/s12248-012-9329-6. Epub 2012 Mar 6.

10.

Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Watson DS, Endsley AN, Huang L.

Vaccine. 2012 Mar 16;30(13):2256-72. doi: 10.1016/j.vaccine.2012.01.070. Epub 2012 Feb 2. Review. Erratum in: Vaccine. 2012 Aug 24;30(39):5799.

11.

Elucidation of the time course of adenosine deaminase APOBEC3G and viral infectivity factor vif in HIV-2(287) -infected infant macaques.

Endsley AN, Ho RJ.

J Med Primatol. 2012 Feb;41(1):52-9. doi: 10.1111/j.1600-0684.2011.00518.x. Epub 2011 Oct 24.

12.

Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines?

Endsley AN, Salama NN, Ho RJ.

Curr HIV Res. 2008 Sep;6(5):401-10. Review.

PMID:
18855650

Supplemental Content

Loading ...
Support Center